Tesamorelin is a stabilized synthetic peptide analogue of endogenous human Growth Hormone-Releasing Hormone (GHRH), comprising the full 44-amino acid sequence of human GHRH with a distinct N-terminal modification [citation:1][citation:2][citation:7]. A trans-3-hexenoic acid group attached to the N-terminus confers resistance to enzymatic degradation by dipeptidyl aminopeptidase (DPP-IV), significantly enhancing pharmacokinetic stability compared to native GHRH [citation:1][citation:7]. As a selective GHRH receptor (GHRHR) agonist, tesamorelin stimulates endogenous pulsatile growth hormone secretion and subsequently increases IGF-1 and IGFBP-3 levels, providing a precise research tool for investigating visceral adipose tissue metabolism, hepatic steatosis, and endocrine regulation in metabolic disease models [citation:2][citation:6][citation:7].